In Figure , the relative growth in the number of documents and the journal/patent ratio for the polyQ disease are compared to those for the general class of neurodegenerative disease. While the growth in the polyQ documents was faster in the previous years, it considerably lags behind that of the general neurodegenerative disease class in the recent decade. This might be a result of the lack of major breakthroughs in the polyQ disease research in recent years. Indeed, while there is a significant research progress in other neurogenerative diseases such as, for example, Alzheimer's disease, which resulted in the recently approved by the US FDA drug lecanemab 180 , and more drugs and treatments on the horizon 181, 182 , as well as for Parkinson's disease, for which the non-invasive ultrasound treatment Exablate Neuro has been recently approved , there is still no cure for any of the polyQ diseases. The higher journal/patent ratio for the general field of neurodegenerative disease as compared to the polyQ disease (Figure ) also points out more active research in the former. The United States, Japan, China, the United Kingdom, Germany, France, Canada, and South Korea are the leaders with respect to the number of published journal articles and patents related to the polyQ disease research, with ~1/3 of the journal articles and ~half of the patents coming from the United States (Figure ). The journals Human Molecular Genetics, Movements Disorders, PLoS One, and Neurology have published the highest number of articles related to general polyQ research (Figure ), while Science, Nature Genetics, and Cell have received the highest average number of citations per article, an indicator of the impact of journal publications (Figure , Inset).